IQVIA Holdings Inc. (IQV) Current Ratio: 0.75
Is IQVIA Holdings Inc.’s current ratio high or low?
IQVIA Holdings Inc.'s current ratio of 0.75 is 16% below its 5-year average of 0.90, near the low end of its 5-year range (0.75–1.12).
As of Thursday, June 11, 2026. 5.66% below its 12-month average of 0.79.
IQV Current Ratio Chart
IQV Average Current Ratio Chart
IQV Current vs Average Current Ratio Chart
IQV Current Ratio Metrics
CURRENT RATIO
0.75
CURRENT RATIO AVG TTM
0.79
CURRENT RATIO AVG 3Y
0.83
CURRENT RATIO AVG 5Y
0.90
CURRENT RATIO AVG 10Y
1.04
CURRENT RATIO AVG 15Y
1.10
CURRENT RATIO AVG 20Y
1.10
CURRENT VS TTM AVG
-5.66%
CURRENT VS 3Y AVG
-10.18%
CURRENT VS 5Y AVG
-16.20%
CURRENT VS 10Y AVG
-28.14%
CURRENT VS 15Y AVG
-32.02%
CURRENT VS 20Y AVG
-32.02%
IQV Competitors' Current Ratio
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $30.08B | 0.75 | 0.79 | 0.83 | 0.90 |
| Medline Inc. (MDLN) | $30.90B | 4.29 | 3.84 | 3.94 | 3.94 |
| Biogen Inc. (BIIB) | $28.94B | 2.68 | 2.02 | 2.25 | 2.11 |
| DexCom, Inc. (DXCM) | $28.92B | 1.88 | 1.67 | 2.04 | 3.15 |
| Centene Corporation (CNC) | $32.26B | 1.68 | 1.40 | 1.24 | 1.19 |
| Veeva Systems Inc. (VEEV) | $26.31B | 4.89 | 4.70 | 4.39 | 4.08 |
| Zoetis Inc. (ZTS) | $34.27B | 3.03 | 2.39 | 2.63 | 2.90 |
| Agilent Technologies, Inc. (A) | $36.21B | 1.96 | 2.02 | 2.17 | 2.21 |
| Waters Corporation (WAT) | $23.21B | 1.73 | 1.92 | 2.08 | 2.07 |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 1.14 | 1.08 | 1.10 | 1.13 |
Liquidity Analysis
Current Ratio
0.75
Quick Ratio
0.75
IQVIA Holdings Inc. Current Ratio Formula & Definition
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IQVIA Holdings Inc. Current Ratio FAQ
- What is the current ratio for IQVIA Holdings Inc. (IQV)?
- The current ratio for IQV stock is 0.75.
- Is IQVIA Holdings Inc.'s current ratio high or low?
- IQVIA Holdings Inc.'s current ratio of 0.75 is 16% below its 5-year average of 0.90, near the low end of its 5-year range (0.75–1.12).
- What is the TTM average current ratio for IQVIA Holdings Inc. (IQV)?
- The TTM average current ratio for IQV stock is 0.79.
- What is the 3Y average current ratio for IQVIA Holdings Inc. (IQV)?
- The 3Y average current ratio for IQV stock is 0.83.
- What is the 5Y average current ratio for IQVIA Holdings Inc. (IQV)?
- The 5Y average current ratio for IQV stock is 0.90.
- What is the 10Y average current ratio for IQVIA Holdings Inc. (IQV)?
- The 10Y average current ratio for IQV stock is 1.04.
- What is the 15Y average current ratio for IQVIA Holdings Inc. (IQV)?
- The 15Y average current ratio for IQV stock is 1.10.
- What is the 20Y average current ratio for IQVIA Holdings Inc. (IQV)?
- The 20Y average current ratio for IQV stock is 1.10.
IQVIA Holdings Inc. Current Ratio History
| DATE | CURRENT RATIO |
|---|---|
| 2025-12-31 | 0.75 |
| 2024-12-31 | 0.84 |
| 2023-12-31 | 0.86 |
| 2022-12-31 | 0.89 |
| 2021-12-31 | 0.91 |
| 2020-12-31 | 1.12 |
| 2019-12-31 | 1.05 |
| 2018-12-31 | 1.10 |
| 2017-12-31 | 1.22 |
| 2016-12-31 | 1.23 |
| 2015-12-31 | 1.51 |
| 2014-12-31 | 1.46 |
| 2013-12-31 | 1.31 |
| 2012-12-31 | 1.15 |
| 2011-12-31 | 1.15 |
Related Metrics
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib